Phase 4 N=75 Insulin Schemes for Type 2 Diabetes Control
Type 2 Diabetes Mellitus
Primary: Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin. — 129.6; 135; 155.4; 156.2 mg/dl
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
N/A N=1,509 Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)
Patients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)
Primary: 1 -Year Survival Probability Rate: Vascular Readmissions or Death — .91; .91 proportion of participants
N/A N=22 Treatment and Recovery Monitoring of Post TBI Symptoms
Brain Injuries, Traumatic
Primary: Change From Baseline in RPQ Score at Post-treatment Sessions — -4.6; -3.4 units on a scale
Phase 2 N=35 Single Dose of pGM169/GL67A in CF Patients
Cystic Fibrosis
Primary: Body Maximum Temperature — 38.6; 38.0; 37.4 celsius — p=0.0002
Phase 1 N=60 CiPA Phase 1 ECG Biomarker Validation Study
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Phase 2 N=15 A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis
Primary: Change in Serum Alkaline Phosphatase (SAP) — 3 Participants — p=.03
N/A N=97 Electric Stimulation of the Eye to Improve Vision After Trauma
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) · Trauma · Multiple Sclerosis (MS)
Primary: Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Acuity — -0.23; -0.14; -0.08; -0.06 logMAR
Phase 2 N=23 A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
Aortic Valve Stenosis
Primary: Changes in Aortic Valve Calcium Levels — 65; 215 Arbitrary Units — p=0.05
Phase 3 N=231 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Aortic Valve Stenosis · Cardiovascular Diseases · Heart Valve Diseases
Primary: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan — 11; 2 Participants — p=0.01
Early Phase 1 N=143 Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery
Emergence Agitation · Pain
Primary: Emergence Agitation (EA) as Measured by Standardized PAED Scale — 5.3; 4.99; 6.29 score on a scale
Phase 2 N=36 Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"
Alpha-1 Antitrypsin Deficiency
Primary: Change From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF) — 4551.023; 13454.772; -27.15 nmol — p=0.0005
N/A N=40 The Comparison of Virtual and Real Boxing Training in Hemiparetic Stroke Patients
Stroke · Hemiparesis
Primary: Wolf Motor Function Test — 68.00; 69.65; 68.65; 71.05 score on a scale — p=0.004
N/A N=12 The MICHI NEUROPROTECTION SYSTEM: Evaluation of Performance in Carotid Artery Stent Procedures (The LOTUS Study)
Carotid Stenosis · Carotid Artery Disease
Primary: Composite of Any Stroke, Myocardial Infarction and Death — 1; 0; 0 participants
N/A N=30 Post Market Clinical Followup of MolecuLight i:X's PPV to Predict Presence of Bacteria in Wounds
Wounds and Injuries
Primary: Positive Predictive Value (PPV) of Localized Red Fluorescence Signals With Microbiological Samples — 100 percentage of PPV of red fluorescence